On October 6, 2022 Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") reported that Dr. Mike A. Royal, Chief Medical Officer, will participate in an upcoming Key Opinion Leader (KOL) Panel Discussion that will focus on the great unmet need in non-small cell lung cancer and the potential of abivertinib, a novel, third-generation, EGFR/BTK inhibitor (Press release, Sorrento Therapeutics, OCT 6, 2022, View Source [SID1234621768]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The KOL Panel Discussion will be archived and can be accessed on the Investor Relations section of Sorrento’s website under Events, where you can also learn more about the panel participants’ backgrounds and biographies. (Events Calendar – Sorrento Therapeutics).